STEVANATO GROUP SPA O.N. (87N) - Total Liabilities
Based on the latest financial reports, STEVANATO GROUP SPA O.N. (87N) has total liabilities worth €1.06 Billion EUR (≈ $1.24 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore STEVANATO GROUP SPA O.N. (87N) cash conversion ratio to assess how effectively this company generates cash.
STEVANATO GROUP SPA O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how STEVANATO GROUP SPA O.N.'s total liabilities have evolved over time, based on quarterly financial data. Check STEVANATO GROUP SPA O.N. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
STEVANATO GROUP SPA O.N. Competitors by Total Liabilities
The table below lists competitors of STEVANATO GROUP SPA O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou KingTeller Technology Co Ltd
SHE:002177
|
China | CN¥25.84 Million |
|
VITZROCELL Co.Ltd
KQ:082920
|
Korea | ₩36.50 Billion |
|
Drägerwerk AG & Co. KGaA
XETRA:DRW8
|
Germany | €1.52 Billion |
|
Prima Andalan Mandiri Tbk PT
JK:MCOL
|
Indonesia | Rp158.96 Million |
|
Zhejiang Shengyang Science
SHG:603703
|
China | CN¥1.10 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥882.65 Million |
|
DNA Link Inc
KQ:127120
|
Korea | ₩54.44 Billion |
|
Shinry Technologies Co Ltd Class A
SHE:300745
|
China | CN¥2.11 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down STEVANATO GROUP SPA O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see STEVANATO GROUP SPA O.N. (87N) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STEVANATO GROUP SPA O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STEVANATO GROUP SPA O.N. (2021–2025)
The table below shows the annual total liabilities of STEVANATO GROUP SPA O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.06 Billion ≈ $1.24 Billion |
+14.39% |
| 2024-12-31 | €924.43 Million ≈ $1.08 Billion |
-1.54% |
| 2023-12-31 | €938.93 Million ≈ $1.10 Billion |
+41.45% |
| 2022-12-31 | €663.79 Million ≈ $776.04 Million |
+15.00% |
| 2021-12-31 | €577.18 Million ≈ $674.79 Million |
-- |
About STEVANATO GROUP SPA O.N.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprisi… Read more